| Hazard Information | Back Directory | [Uses]
IONIS-FB-LRx is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). IONIS-FB-LRx effectively reduces circulating levels of CFB. IONIS-FB-LRx can be used for geographic atrophy (GA) research[1][2]. | [in vivo]
IONIS-FB-Lrx is administered by subcutaneous injection every four weeks and targets CFB’s hepatic expression[2]. | [References]
[1] Dreismann AK, et al. Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway. Immunol Rev. 2022 Nov 12. DOI:10.1111/imr.13149
[2] Mahmoudzadeh R, et al. Emerging treatments for geographic atrophy in age-related macular degeneration. Curr Opin Ophthalmol. 2021 May 1;32(3):294-300. DOI:10.1097/ICU.0000000000000746 |
|
|